Blood test may predict Crohn's drug success
NCT ID NCT03142321
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at whether certain proteins in the blood can predict if the drug vedolizumab (Entyvio) will reduce inflammation in the small bowel of people with Crohn's disease. Researchers used MRI scans to measure changes in the bowel wall after treatment. The goal is to help doctors choose the right treatment earlier for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vedolizumab (Entyvio) injection
- What this could lead to
- If successful, this could help doctors predict which patients with small bowel Crohn's will respond to vedolizumab, allowing more personalized treatment.
- What could go wrong
- This is a small, completed Phase 4 study focused on finding biomarkers, not proving a new treatment works. The results may not apply to all Crohn's patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE OF SMALL INTESTINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.